Valeant Receives FDA Complete Response Letter for Vyzulta

August 11, 2017: By Jon Swedien

1 Ophthalmic NewsValeant Pharmaceuticals International has received a complete response letter (CRL) from the US FDA in response to its new drug application (NDA) for Vyzulta, the Canadian company announced Aug. 7.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) is a nitric oxide-donating prostaglandin analog intended to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to Valeant, the CRL references a current good manufacturing practice (CGMP) inspection at a Tampa, Florida, manufacturing facility belonging to its Bausch + Lomb subsidiary.

The company said the FDA did not identify any efficacy or safety concerns or request additional clinical trials for NDA approval.

Valeant said it will work closely with the agency to determine the next steps.

The US FDA had set a target action date of Aug. 24, 2017, for its decision on Vyzulta.

Bausch + Lomb and Nicox are co-developing the drug candidate. The two companies had resubmitted the NDA in early March after addressing concerns the FDA raised in a 2016 inspection of the Tampa facility.

Bausch + Lomb licensed the product candidate from Nicox in March 2010 and rebranded the drug Vyzulta in January. It was previously branded Vesneo.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023